Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
Medical Xpress – latest medical and health news stories
